Investigational drug · Phase 3
Clemizole HCl
Also called: EPX-100
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dravet Syndrome, Lennox Gastaut Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "Clemizole HCl"
First trial start
2020
Sep 15, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Clemizole HCl", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dravet Syndrome
- Lennox Gastaut Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Clemizole HCl" as an intervention, largest first.
- An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromePivotal-lookingRecruiting
EpygenixIndustry
NCT05066217 · 260 participants (planned) · Start Apr 9, 2025 · Primary completion Nov 1, 2026
Drug: Clemizole HCl; Placebo · For: Lennox Gastaut Syndrome
Sites: Little Rock, Arkansas; Orange, California; Miami, Florida · 71 sites in all
- A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromePivotal-lookingRecruiting
EpygenixIndustry
NCT04462770 · 150 participants (planned) · Start Sep 15, 2020 · Primary completion Apr 2027
Drug: Clemizole HCl; Placebo · For: Dravet Syndrome
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 86 sites in all
EpygenixIndustry
NCT07879170 · 88 participants (planned) · Start Aug 5, 2026 · Primary completion Dec 30, 2026
Drug: EPX-100; EPX-100-Matching Placebo and 2 more · For: Healthy Participants
Sites: Tempe, Arizona
EpygenixIndustry
NCT07824193 · 54 participants · Start Jan 15, 2025 · Primary completion Apr 3, 2025
Drug: EPX-100; Itraconazole and 4 more · For: Drug Drug Interaction
Sites: Tempe, Arizona
EpygenixIndustry
NCT04069689 · 24 participants · Start Aug 29, 2019 · Primary completion Nov 27, 2019
Drug: EPX-100 (Clemizole Hydrochloride); Placebos · For: Dravet Syndrome
Sites: Fair Lawn, New Jersey
- Clemizole HCl for Subjects With Hepatocellular CarcinomaStatus unknown
Eiger Group International, Inc.Industry
NCT03069508 · 12 participants (planned) · Start Feb 13, 2017 · Primary completion Dec 31, 2017
Drug: Clemizole Hydrochloride · For: Hepatocellular Carcinoma
Sites: Ankara, Turkey (Türkiye)
Eiger BioPharmaceuticalsIndustry
NCT00945880 · 12 participants · Start Jul 2009 · Primary completion Aug 2010
Drug: clemizole hydrochloride · For: Hepatitis C
Newest research
PubMed records naming it or its code names, newest first.
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome.
Miziak B, Czuczwar S · Expert Opin Drug Discov 2021
Also in development for Dravet Syndrome
- LP352bexicaserinPhase 34 trials
Longboard Pharmaceuticals · Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox-Gastaut Syndrome
- zorevunersenSTK-001Phase 32 trials
Stoke Therapeutics, Inc · Dravet Syndrome
- ETX101Phase 23 trials
Encoded Therapeutics · Dravet Syndrome
- BMB-101Phase 22 trials
Bright Minds Biosciences Pty Ltd · Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome
- ION337Phase 21 trial
Ionis Pharmaceuticals · Dravet Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.